[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-464524-105":59,"doc-detail-464524-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","personalizing-treatment-for-pancreatic-ductal-adenocarcinoma-the-emerging-role-of-minimal-residual-disease-in-perioperative-decision-making","Personalizing Treatment for Pancreatic Ductal Adenocarcinoma - The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making","","Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor long-term survival, even after advances in surgery, systemic therapy, and perioperative management. Curative-intent resection is followed by frequent systemic recurrence, indicating that many patients retain minimal residual disease (MRD): microscopic tumor burden persisting after surgery and remaining undetected by conventional diagnostics. Liquid biopsy techniques, especially circulating tumor DNA (ctDNA), enable non-invasive MRD detection and reveal prognostic value, relapse risk, and guidance for personalized perioperative strategies. The review consolidates MRD biology, detection methods, perioperative risk stratification, treatment implications, and future integration into clinical practice.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/personalizing-treatment-for-pancreatic-ductal-adenocarcinoma-the-emerging-role-of-minimal-residual-disease-in-perioperative-decision-making/464524/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/personalizing-treatment-for-pancreatic-ductal-adenocarcinoma-the-emerging-role-of-minimal-residual-disease-in-perioperative-decision-making/464524.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is minimal residual disease (MRD) important in pancreatic ductal adenocarcinoma (PDAC) after curative surgery?","Question",{"text":112,"@type":113},"Because many patients experience recurrence despite curative-intent resection, indicating that microscopic tumor burden persists postoperatively and is not detected by conventional imaging.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How can circulating tumor DNA (ctDNA) support personalized perioperative decision-making?",{"text":117,"@type":113},"ctDNA offers a non-invasive way to detect MRD and to identify patients at higher relapse risk earlier, enabling tailored perioperative management and improved risk stratification.",{"name":119,"@type":110,"acceptedAnswer":120},"What is required before MRD assessment can be implemented in routine clinical practice?",{"text":121,"@type":113},"Extensive validation in well-designed prospective trials is necessary to confirm performance and guide transition to clinical use.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},464524,1790871432,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Review  \nPersonalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making  \nCharalampos Theocharopoulos 1,*, Nikolaos Machairas 2,3, Ioannis A. Ziogas 1, Benedetto Mungo 1, Marco Del Chiaro 1, Georgios K. Glantzounis 4, Richard Schulick 1 and Georgios C. Sotiropoulos 3  \nAcademic Editor: Samuel C. Mok  \nReceived: 24 November 2025  \nRevised: 19 December 2025  \nAccepted: 24 December 2025  \nPublished: 27 December 2025  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA  \n2 2nd Department of Propaedeutic Surgery, National and Kapodistrian University of Athens,  \n11527 Athens, Greece  \n3 Department of Liver Transplantation and Hepatobiliary Surgery, National and Kapodistrian University of Athens, 11527 Athens, Greece  \n4 Department of Surgery, University Hospital of Ioannina, 45500 Ioannina, Greece  \n* Correspondence: [charalampos.theocharopoulos@cuanschutz.edu](charalampos.theocharopoulos@cuanschutz.edu)  \nSimple Summary  \nDespite curative-intent surgery, many patients with pancreatic ductal adenocarcinoma experience disease recurrence due to undetected systemic spread. Circulating tumor DNA provides a non-invasive approach to identify minimal residual disease and to detect patients at high risk of relapse earlier. Emerging evidence indicates that ctDNA has strong potential to guide personalized perioperative management and improved risk stratification. Extensive validation in well-designed prospective trials is necessary before transition to clinical implementation.  \nAbstract  \nPancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor long-term survival despite advances in surgical techniques, systemic therapies, and perioperative management. High rates of systemic recurrence following curative-intent resection suggest that many patients harbor minimal residual disease (MRD), microscopic tumor burden that persists postoperatively and remains undetectable by conventional diagnostic tools. Recent advances in liquid biopsy technologies, particularly circulating tumor DNA (ctDNA) analysis, alongside detailed characterization of the PDAC mutational landscape, offer a promising non-invasive approach for MRD detection. Emerging evidence indicates that MRD status can serve as a sensitive prognostic biomarker, identify patients at high risk of relapse, and guide personalized perioperative therapy, including optimization of adjuvant treatment. This review summarizes current knowledge on the biology and detection of MRD in PDAC, its implications for perioperative risk stratification and treatment decision-making, and discusses future directions for integrating MRD assessment into clinical practice to enable more precise, individualized patient management.  \nKeywords: pancreatic ductal adenocarcinoma; minimal residual disease; circulating tumor cells; circulating tumor DNA; adjuvant treatment; neoadjuvant treatment; pancreatoduodenectomy  \n1. Introduction  \nPancreatic ductal adenocarcinoma (PDAC) is the second most common gastrointestinal malignancy and the third leading cause of cancer-related death in the United States. According to the American Cancer Society, 67,440 new cases and 51,980 PDAC-related deaths are projected to occur in 2025 [1] . Concerningly, PDAC is estimated to overtake colorectal cancer before 2040, becoming the second leading cause of cancer-related mortality following lung cancer [2] .  \nAlthough surgical resection remains the only potentially curative treatment, most patients present late during the disease course and are not considered eligible for curativeintent resection. Patients not amenable to surgery are thus treated with systemic therapies, which, despite recent ","cbCaitkZsxDmKKXz","https://ap.wps.com/l/cbCaitkZsxDmKKXz","pdf",757843,"English","# Introduction\n## Clinical challenge and recurrence after resection\n## Systemic therapy context in metastatic and resectable disease\n## Rationale for minimal residual disease assessment\n# Emerging role of ctDNA and perioperative use\n## Liquid biopsy approaches\n## MRD as prognostic biomarker and risk stratification","[{\"question\":\"Why is minimal residual disease (MRD) important in pancreatic ductal adenocarcinoma (PDAC) after curative surgery?\",\"answer\":\"Because many patients experience recurrence despite curative-intent resection, indicating that microscopic tumor burden persists postoperatively and is not detected by conventional imaging.\"},{\"question\":\"How can circulating tumor DNA (ctDNA) support personalized perioperative decision-making?\",\"answer\":\"ctDNA offers a non-invasive way to detect MRD and to identify patients at higher relapse risk earlier, enabling tailored perioperative management and improved risk stratification.\"},{\"question\":\"What is required before MRD assessment can be implemented in routine clinical practice?\",\"answer\":\"Extensive validation in well-designed prospective trials is necessary to confirm performance and guide transition to clinical use.\"}]","Personalizing Treatment for Pancreatic Ductal Adenocarcinoma - The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making | PDF",1790768307,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/b2d4d471777046649a5ab724ac72a4d3.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/514ded6e6cad0282154120be74b37b92.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/9cf4ecd0ef3f56ec1951d32632771d4f.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/fb4010745fc4d08cc822a39961d989d4.webp",980,1385]